euro adhoc: Sygnis Pharma AG / Restructuring & Recapitalisations / SYGNIS Pharma AG Approves Capital Increase

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

15.10.2008

SYGNIS Pharma AG Approves Capital Increase

Heidelberg, October 15, 2008 - Today the Management Board of the
Heidelberg biotechnology company SYGNIS Pharma AG (Frankfurt: LIO;
ISIN DE0005043509; Prime Standard) with the consent of the
Supervisory Board approved an increase of the company's share capital
of EUR 28,563,676.00 by EUR 12,694,967.00 to EUR 41,258,643.00 by
means of the issuance of 12,694,967 shares of common bearer stock
without nominal value from authorized capital. The new shares will be
subscribed to by Sal. Oppenheim jr. & Cie KGaA, Frankfurt am Main
("Sal. Oppenheim") subject to the requirement that it will offer the
shares for purchase to the company shareholders. As the shareholders'
subscription rights are secured the shareholders can subscribe to the
new shares, which will include dividend participation rights
starting April 01, 2008, at a ratio of 9:4 during the period
commencing October 21, 00:00 Central European Summer Time and ending
November 04, 2008, 12:00 pm (noon) Central European Time at a
subscription price of EUR 1.44 per new share. It may also be possible
to subscribe to additional new shares. The new shares will not be
offered in a public offering. The new shares will have full profit
participation rights for the fiscal year starting April 1, 2008. The
listing of the new shares will occur at a later date. Further details
on the capital increase will be contained in the subscription offer
which is expected to be published in the electronic Bundesanzeiger on
October 20, 2008. The major shareholders dievini Hopp BioTech holding
GmbH & Co. KG and BASF SE have committed to Sal. Oppenheim jr. & Cie.
KGaA to fully exercise the subscription rights to which they are
entitled by virtue of their share ownership. They have further
committed to Sal. Oppenheim jr. & Cie. KGaA to acquire all new shares
that are not subscribed to by other shareholders at the subscription
price. The company will use the total net proceeds which are expected
to be more than EUR 18 million for the clinical development of AX200
for use in the treatment of acute stroke, the further development of
the existing project pipeline and the expansion of the pipeline by
new projects. This notice is for information purposes only, and does
not constitute an offer for the sale of or a solicitation of offers
for the purchase of subscription rights or securities in the United
States of America (USA), Germany, or any other jurisdiction.
Subscription rights and securities may not be offered or sold without
registration or an exemption from the registration requirement under
the US Securities Act of 1933 as amended and the securities laws of
the individual US states. SYGNIS Pharma AG does not intend to
register any portion of this offer in the USA or to make a public
offering of subscription rights or securities.

For further information, please contact:

Dr. Franz-Werner Haas
VP Operations / General Counsel
Tel: +49 (0) 6221-454 812
Email: franz-werner.haas@sygnis.de

###

Certain statements contained in this press release, which are neither
documented financial results or other historical data, are
prospective in nature. This refers in particular to prognoses of
future events, trends, plans, or goals. Such statements must not be
considered absolutely certain, as they are by their nature subject to
known and unknown risks, and can be influenced by other factors, as a
result of which the actual results, plans, and goals of SYGNIS may
substantially differ from the express or implied forward-looking
statements. SYGNIS undertakes no obligation to publicly update or
revise these statements, either in the light of new information or
future events, or for other reasons. ###

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Simone Angstmann

Executive Assistant

Telefon: +49(0)6221 454-852

E-Mail: simone.angstmann@sygnis.de

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade